The association between type 2 diabetes and pulmonary cavitation revealed among IGRA-positive tuberculosis patients

Front Med (Lausanne). 2023 Dec 6:10:1245316. doi: 10.3389/fmed.2023.1245316. eCollection 2023.

Abstract

The co-occurrence of tuberculosis (TB) and diabetes mellitus (DM) presents a significant obstacle to TB eradication. Pulmonary cavitation can occur in severe cases of TB, particularly in patients with DM. From 1 May 2014 through 30 June 2019, we conducted a cross-sectional study of 1,658 smear- or culture-confirmed pulmonary TB (PTB) patients at the Second Department of Pulmonary Medicine and Tuberculosis, Shenzhen, China. A total of 861 participants who satisfied the criteria (chest CT scan for cavitation, interferon-gamma release assay (IGRA), diagnosis of diabetes mellitus), with the median age of 36.7 years, 63.6% of male, 79.7% IGRA positive, 13.8% with diabetes, and 40.8% with pulmonary cavitation, were included in the study. The association between diabetes and pulmonary cavitation was confirmed in these TB patients (adjusted OR, 2.54; 95% CI, 1.66-3.94; p < 0.001). No associations were observed between diabetes and IGRA, as well as between lung cavitary and IGRA. Based on the criteria of IGRA+/-, pulmonary cavitation+/-, and DM+/-, the further analysis with univariate and multivariate logistic regression were conducted in six subgroups. The significant association between diabetes and pulmonary cavitation was further confirmed in the IGRA+ subgroup (adjusted OR, 3.07; 95% CI, 1.86-5.16; p < 0.001) but not observed in IGRA- individuals. This observation suggests that different immunological mechanisms of pulmonary cavitary/DM may be employed in IGRA+ TB patients from IGRA- TB patients.

Keywords: diabetes mellitus; interferon-gamma; pulmonary cavitation; risk factor; tuberculosis.

Grants and funding

The authors acknowledge the support by Financial Funds of Shenzhen Municipality, Shenzhen High-level Hospital Construction Fund (Nos. G2021010, G2021022, and 22240G1003), the National Natural Science Foundation of China (No. 82070016), Shenzhen Clinical Research Center for Tuberculosis (No. 20210617141509001), and Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties (No. SZGSP010).